• Search

Parental MCF7 Breast Cancer Cells (MCF7/S0.5)

Parental MCF7 Breast Cancer Cells (MCF7/SO.5).

Product Code: ax4010 Categories: , .

Payment Options

We accept Visa and MasterCard in our online store.

Worldwide Shipping

We can get your purchases to you wherever you are.

Customer Care

As an Axol customer you have access to our support team and product specialists.


MCF7/S0.5 was adapted to grow in low-serum culture medium to reduce estrogen exposure from fetal bovine serum. This permits the cells to be used for experiments studying hormone signaling and the effects of drugs that target hormone receptors. This line was used as the parental line from which the tamoxifen-resistant and fulvestrant-resistant MCF7 cell lines were generated. Therefore, drug sensitive and resistant matched cell lines are available.

Condition of sale: the end user is not permitted to transfer or re-freeze the cells.

Product Specification

Donor gender Female
Donor age at sampling 69 yrs
Genetic modification None
Size 1 million cells
Growth properties Adherent
Disease information Malignant adenocarcinoma derived from pleural effusion
General notes Expresses the estrogen receptor (ER)
Shipping conditions Dry ice
Storage conditions vapour phase nitrogen
Usage notes Culture in DMEM/F12 medium (no phenol red) supplemented with 1% fetal bovine serum + 2.5 mM GlutaMAX + 6 ng/mL insulin
Condition of sale The end user is not permitted to transfer or re-freeze the cells

Technical Resources


  • Briand P, Lykkesfeldt AE. Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Research (1984)
  • Lykkesfeldt AE, Briand P. Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. British Journal of Cancer (1986)
  • Lykkesfeldt AE, Laursen I, Briand P. Regulation of the secretion of proteins synthesized by the human breast cancer cell line, MCF-7. Molecular and Cellular Endocrinology (1989)
  • Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Research (2014)
  • Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. International Journal of Cancer (1995)
  • Sonne-Hansen K, Lykkesfeldt AE. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J Steroid Biochem Mol Biol. (2005)
  • Thomsen KG, Lyng MB, Elias D et al. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients. Breast Cancer Research and Treatment (2015)
  • Alves CL, Elias D, Lyng M et al. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical Cancer Research (2016)
  • Joshi T, Elias D, Stenvang J et al. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. Oncotarget (2016)
  • Hole S, Pedersen AM, Hansen SK et al. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. International Journal of Cancer (2015)